title: Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells.
abstract: The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms of inherited resistance, sensitive versus resistant individuals were selected from a survey of 92 immortalized lymphoblastoid B-cell lines from normal individuals. Levels of CD20 protein and surface expression were lower in the resistant group. In contrast, CD20 mRNA levels were not correlated with susceptibility, suggesting regulation at a post-transcriptional level. To examine acquired resistance, resistant sublines were selected from both lymphoblastoid as well as lymphoma cell lines. Confirming previous findings, there was significant down-regulation of CD20 protein expression in all the resistant sublines. CD20 mRNA splice variants are reported to be associated with development of resistance. Three splice variants were observed in our cell lines, each lacking the binding epitope for rituximab, but none were associated with rituximab resistance. The second generation anti-CD20 mAb, ofatumumab, was more active compared with rituximab in vitro in the survey of all B-cell lines, mirroring results that have been reported previously with malignant B-cells. These studies show that normal B-lymphoblastoid cell lines can be used to model both innate and acquired mechanisms of resistance. They validate the important role of CD20 expression and enable future genetic studies to identify additional mediators of anti-CD20 mAb resistance.
authors: Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill , NC , USA ; Division of Hematology/Oncology , University of North Carolina at Chapel Hill , NC , USA ; UNC Institute for Pharmacogenomics and Individualized Therapy , University of North Carolina at Chapel Hill , NC , USA.
authors: George W
authors: GW
authors: Small
authors: Howard L
authors: HL
authors: McLeod
authors: Kristy L
authors: KL
authors: Richards
keywords: CD20 expression; Complement-dependent cytotoxicity; Drug resistance; Lymphoblastoid cell line; Ofatumumab; Rituximab; mRNA splice variants
references: J Immunol. 2006 Jul 1;177(1):362-71
references: 16785532
references: Int Immunopharmacol. 2009 Jan;9(1):10-25
references: 19000786
references: J Immunol. 2009 Jul 1;183(1):749-58
references: 19535640
references: J Clin Neuromuscul Dis. 2010 Dec;12(2):91-102
references: 21386778
references: J Immunol. 1998 Oct 1;161(7):3242-8
references: 9759838
references: Clin Cancer Res. 2010 Sep 1;16(17):4331-8
references: 20601446
references: Clin Cancer Res. 2011 Nov 1;17(21):6702-11
references: 21918174
references: Mol Cancer Ther. 2011 Oct;10(10):1839-45
references: 21750217
references: Clin Cancer Res. 2011 Aug 15;17(16):5490-500
references: 21705454
references: J Clin Oncol. 1998 Aug;16(8):2825-33
references: 9704735
references: Biochem Biophys Res Commun. 2009 Dec 4;390(1):48-53
references: 19769942
references: J Immunol. 2003 Aug 1;171(3):1581-7
references: 12874252
references: Cancer Res. 2003 Jan 15;63(2):534-40
references: 12543813
references: Neth J Med. 2009 Jul-Aug;67(7):251-9
references: 19687518
references: Blood. 2010 Mar 25;115(12):2420-9
references: 20089966
references: J Biol Chem. 2008 Jul 4;283(27):18545-52
references: 18474602
references: Cancer Res. 2008 Apr 1;68(7):2400-8
references: 18381448
references: J Biol Chem. 1988 Jul 15;263(20):10009-15
references: 2454914
references: Haematologica. 2010 Jan;95(1):135-43
references: 19773256
references: J Clin Oncol. 2000 Sep;18(17):3135-43
references: 10963642
references: J Clin Oncol. 2003 Nov 1;21(21):3940-7
references: 12975461
references: Clin Cancer Res. 2006 Jul 1;12(13):4027-35
references: 16818702
references: Blood. 2009 Mar 5;113(10):2145-53
references: 19109566
references: Blood. 2001 Nov 1;98(9):2771-7
references: 11675350
references: Blood. 1998 Mar 1;91(5):1644-52
references: 9473230
references: J Clin Oncol. 2010 Jul 20;28(21):3525-30
references: 20458041
references: Annu Rev Med. 2008;59:237-50
references: 18186705
references: Cancer Immunol Immunother. 2002 Mar;51(1):15-24
references: 11845256
references: Blood. 2010 Jun 24;115(25):5191-201
references: 20223920
references: J Immunol. 1989 Apr 1;142(7):2560-8
references: 2466899
references: Clin Cancer Res. 2008 Oct 15;14(20):6697-703
references: 18927313
references: Pharmacogenomics. 2011 Oct;12(10):1407-15
references: 22008047
references: Blood. 2001 Mar 1;97(5):1392-8
references: 11222385
references: Clin Cancer Res. 2009 Apr 1;15(7):2523-30
references: 19276251
references: Leuk Res. 2006 May;30(5):625-31
references: 16289746
references: Blood. 2004 Sep 15;104(6):1793-800
references: 15172969
references: Clin Cancer Res. 2008 Mar 1;14(5):1561-70
references: 18316581
references: J Clin Aesthet Dermatol. 2009 May;2(5):29-37
references: 20729962
references: J Immunol. 2006 Feb 15;176(4):2600-9
references: 16456022
references: EMBO Rep. 2008 Nov;9(11):1087-93
references: 18846105
references: Mol Immunol. 1998 Mar;35(4):207-14
references: 9736336
references: MAbs. 2010 Jan-Feb;2(1):14-9
references: 20081379
references: Blood. 2001 Dec 1;98(12):3383-9
references: 11719378
references: Blood. 2003 Feb 1;101(3):1045-52
references: 12393541